Jefferies Group restated their buy rating on shares of Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) in a research report released on Monday. They currently have a $3.00 target price on the biopharmaceutical company’s stock.
MRNS has been the subject of several other reports. Zacks Investment Research raised shares of Marinus Pharmaceuticals from a hold rating to a buy rating and set a $1.50 price objective for the company in a report on Tuesday, July 5th. Goldman Sachs Group Inc. downgraded shares of Marinus Pharmaceuticals from a buy rating to a neutral rating in a report on Tuesday, June 14th. Royal Bank Of Canada downgraded shares of Marinus Pharmaceuticals from an outperform rating to a sector perform rating and decreased their price objective for the stock from $14.00 to $2.00 in a report on Tuesday, June 14th. Stifel Nicolaus reaffirmed a hold rating on shares of Marinus Pharmaceuticals in a report on Tuesday, June 28th. Finally, Oppenheimer Holdings Inc. downgraded shares of Marinus Pharmaceuticals from an outperform rating to a market perform rating in a report on Tuesday, June 14th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Marinus Pharmaceuticals currently has a consensus rating of Hold and a consensus price target of $7.90.
Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) traded down 1.761% during trading on Monday, reaching $1.729. 48,362 shares of the company’s stock were exchanged. The company has a 50 day moving average of $1.73 and a 200 day moving average of $3.26. The firm’s market capitalization is $33.73 million. Marinus Pharmaceuticals has a 52-week low of $1.19 and a 52-week high of $10.24.
Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by $0.08. Equities analysts anticipate that Marinus Pharmaceuticals will post ($1.65) earnings per share for the current fiscal year.
In other Marinus Pharmaceuticals news, major shareholder Vii Lp Canaan sold 20,589 shares of the stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $1.81, for a total value of $37,266.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.00% of the stock is currently owned by company insiders.
A hedge fund recently raised its stake in Marinus Pharmaceuticals stock. Franklin Resources Inc. increased its position in shares of Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) by 14.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,182,185 shares of the biopharmaceutical company’s stock after buying an additional 279,900 shares during the period. Franklin Resources Inc. owned approximately 15.22% of Marinus Pharmaceuticals worth $11,740,000 at the end of the most recent quarter. 45.64% of the stock is currently owned by hedge funds and other institutional investors.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.